Status:
TERMINATED
Randomized Controlled Trial of Intranasal Ketamine vs. Intranasal Midazolam in Individuals With OCD
Lead Sponsor:
New York State Psychiatric Institute
Conditions:
Obsessive-Compulsive Disorder
Eligibility:
All Genders
18-55 years
Phase:
PHASE2
Brief Summary
Obsessive-compulsive disorder (OCD) is a common illness that causes significant distress and impairment. Currently, serotonin reuptake inhibitors (SRIs) are the only medications that are FDA-approved ...
Eligibility Criteria
Inclusion
- Age 18-55
- Physically healthy and not currently pregnant
- Primary diagnosis of OCD
- Sufficient severity of symptoms
- For all patients on medications, medications dose must be stable for at least 6 weeks prior to enrollment. Must discuss with Dr. current medications and doses.
- Able to provide consent
Exclusion
- First degree relative with schizophrenia
- Psychiatric conditions that would make participation unsafe determined by study doctor
- Female patients who are either pregnant or nursing
- Planning to start EX/RP during the period of the study or those who have completed an adequate dose of EX/RP (defined as 8 or more sessions within 2 months) within 8 weeks prior to enrollment.
- Nasal obstruction or history of nasal surgery
- Currently on psychotropic medication or other medication likely to interact with the glutamate system
- Medical conditions that make participation unsafe
- Allergy or intolerance to ketamine or midazolam
Key Trial Info
Start Date :
September 1 2014
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
May 1 2015
Estimated Enrollment :
2 Patients enrolled
Trial Details
Trial ID
NCT02206776
Start Date
September 1 2014
End Date
May 1 2015
Last Update
May 3 2017
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
New York State Psychiatric Institute
New York, New York, United States, 10032